Scholar Rock Resubmits Apitegromab BLA, Strengthening FDA Alignment and Supply Chain for SMA Treatment

Apitegromab BLA Returns with Dual Facility Approach—FDA Acceptance Anticipated in 30 Days

Scholar Rock has officially resubmitted its Biologics License Application (BLA) to the U.S. FDA for apitegromab — a candidate aimed at treating both children and adults with spinal muscular atrophy (SMA). Distinctively, this resubmission now incorporates two U.S.-based fill-finish facilities: Catalent Indiana (now part of Novo Nordisk) and a newly qualified second facility. This dual-provider strategy addresses prior FDA site concerns and is closely aligned with recent regulatory guidance.

The resubmission follows extensive dialogue and positive Type A and Type C meetings with the FDA, with Scholar Rock, Catalent Indiana, and the agency reaching consensus on the best pathway forward. As a result, the company expects the FDA to accept the BLA within the next 30 days, with a potential decision (PDUFA date) anticipated by late September 2026. Notably, updates in the BLA are described as limited, containing primarily a standard safety update.

FDA and EMA Review Timelines Point to Potential Global Launch in 2026

Regulatory momentum is building not only in the U.S., but also in Europe, where the EMA’s consideration of apitegromab’s Marketing Authorization Application is on track for a mid-2026 decision. Scholar Rock is positioning for synchronized launches in both regions, enabled by supply chain upgrades and the inclusion of a second fill-finish facility—an approach likely to reassure both regulators and investors about consistent product availability.

The table below summarizes the expected approval timelines and key regulatory milestones:

Pivotal Trial Results Support Potential First-in-Class Launch

Apitegromab stands apart as the first muscle-targeted therapy to achieve statistically significant and clinically meaningful improvements in motor function for SMA patients, as demonstrated in a pivotal Phase 3 trial alongside existing SMN-targeted therapies. This favorable clinical outcome continues to fuel regulatory designations on both continents, including FDA Fast Track, Orphan Drug, Priority Review, and Rare Pediatric Disease, in addition to EMA’s PRIME and Orphan Medicinal Product status.

Supply Chain and Regulatory Collaboration Minimize Approval Risks

Scholar Rock’s rapid response to an earlier Complete Response Letter (CRL)—which cited issues at Catalent Indiana unrelated to apitegromab itself—illustrates a proactive approach to regulatory risk. No further corrective actions were requested following Novo Nordisk’s remediation plan, and the inclusion of a second fill-finish facility further mitigates single-point supply risks. This comprehensive compliance effort is likely to streamline the FDA’s review process.

Key Takeaway: Apitegromab Poised for Late 2026 FDA, EMA Milestones

With regulatory alignment, robust supply chain preparation, and compelling clinical data, Scholar Rock is positioning apitegromab for a potential market debut as the only muscle-targeted therapy for SMA in the U.S. and Europe. While regulatory approval is never guaranteed, timelines and FDA feedback suggest a high likelihood of decision by late September 2026. Investors and stakeholders may want to monitor forthcoming updates, as a positive outcome would represent a major milestone for the SMA community, and for the company’s strategic roadmap.

For those wishing to explore further details or listen in on management’s views, Scholar Rock is hosting a webcast conference call today at 8:00am ET, with replay available for 90 days on its investor relations website.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI